VICh-ASSOTsIIROVANNAYa NEFROPATIYa: STRATEGIYa DIAGNOSTIKI I LEChENIYa


Cite item

Full Text

Abstract

Pathogenesis, clinical and laboratory signs and symptoms, as well as the natural history and treatment, including highly active antiretroviral therapy, are discussed

About the authors

N A Mukhin

V V Fomin

References

  1. Winston J.A. HIV and CKD epidemiology. Adv. Chronic Kidney Dis. 2010; 17(1): 19-25.
  2. Ross M.J., Klotman P.E. Recent progress in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2002; 13: 2997-3004.
  3. Rao T.K., Filippone E.J., Nicastri A.D. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1984; 310:669-673.
  4. Pardo V., Aldana M., Colton R.M. et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann. Intern. Med. 1984; 101:429-434.
  5. Ahuja T.S., Borucki M., Funtanilla M. et al. Is the prevalence of HIV-associated nephropathy decreasing? Am. J. Nephrol. 1999; 19(6): 655-659.
  6. Shahinian V., Rajaraman S., Borucki M. et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am. J. Kidney Dis. 2000; 35(5): 884-888.
  7. Kopp J.B., Winkler C. HIV-associated nephropathy in African Americans. Kidney Int. 2003; Suppl: S43-S49.
  8. Lucas G.M., Mehta S.H., Atta M.G. et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV seronegative participants followed between 1988 and 2004. AIDS. 2007; 21(18): 2435-2443.
  9. Yalavarthy R., Smith M.L., Edelstein C.L. HIV-associated nephropathy in Caucasians: case report and review of literature. Int. J. STD. AIDS. 2008; 19(11): 789-790.
  10. Cheung C.Y., Wong K.M., Lee M.P. et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol. Dial. Transplant. 2007; 22(11): 3186-3190.
  11. D'Agati V., Suh J.I., Carbone L. et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989; 35: 1358-1370.
  12. Nagata M., Hattori M., Hamano Y. et al. Origin and phenotypic features of hyperplastic epithelial cells in collapsing glomerulopathy. Am. J. Kidney Dis. 1998; 32: 962-969.
  13. Rey L., Viciana A., Ruiz P. Immunopathological characteristics of in situ T-cell subpopulations in human immunodeficiency virus-associated nephropathy. Hum. Pathol. 1995;26:408-415.
  14. Rosenstiel P.E., Gruosso T., Letourneau A.M. et al. HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int. 2008; 74(8): 1049-1058.
  15. Chander P., Soni A., Suri A. et al. Renal ultrastructural markers in AIDSassociated nephropathy. Am. J. Pathol. 1987; 126: 513-526.
  16. Ross M.J., Bruggeman L.A., Wilson P.D. et al. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2001; 12: 2645-2651.
  17. Barisoni L., Kriz W., Mundel P. et al. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61.
  18. Lu T.C., He J.C., Klotman P.E. Podocytes in HIV-associated nephropathy. Nephron Clin. Pract. 2007; 106(2): c67-с71.
  19. Husain M., D'Agati V.D., He J.C. et al. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS. 2005; 19(17): 1975-1980
  20. He J.C., Husain M., Sunamoto M. et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J. Clin. Invest. 2004; 114(5): 643-651
  21. Husain M., Gusella G.L., Klotman M.E. et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 2002; 13(7): 1806-1815.
  22. Schwartz E.J., Cara A., Snoeck H. et al. Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J. Am. Soc. Nephrol. 2001; 12(8): 1677-1684.
  23. Sunamoto M., Husain M., He J.C. et al. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int. 2003; 64(5): 1695-1701.
  24. Korgaonkar S.N., Feng X., Ross MD. et al. HIV-1 upregulates VEGF in podocytes. J. Am. Soc. Nephrol. 2008; 19(5): 877-883.
  25. Mikulak J., Singhal P.C. HIV-1 and kidney cells: understanding of viral interaction. Nephron. Exp. Nephrol. 2010; 115:e15-e21.
  26. Mikulak J., Singhal P.C. HIV-1 entry into human podocytes is mediated through lipid rafts. Kidney Int. 2010; 77(1): 72-73.
  27. Gummuluru S., Rogel M., Stamatatos L. et al. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J. Virol. 2003; 77: 12865-12874.
  28. Sakurai N., Kuroiwa T., Ikeuchi H. et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol. Dial. Transplant. 2009; 24(8): 2378-2383.
  29. Arora S., Husain M., Kumar D. et al. Human immunodeficiency virus downregulates podocyte apoE expression. Am. J. Physiol. Renal. Physiol. 2009; 297(3): F653-F661.
  30. Chen G., Paka L., Kako Y. et al. Protective role for kidney apolipoprotein E: regulation of mesangial cell proliferation and matrix expansion. J. Biol. Chem. 2001; 276: 49142-49147.
  31. Singhal P.C., Sharma P., Reddy K. et al. HIV-1 gp160 envelope protein modulates proliferation and apoptosis in mesangial cells. Nephron 1997; 76: 284-295.
  32. Kapasi A.A., Fan S., Singhal P.C. Role of 14-3-3epsilon, c-Myc/Max, and Akt phosphorylation in HIV-1 gp 120-induced mesangial cell proliferation. Am. J. Physiol. Renal Physiol. 2001; 280:F333-F342.
  33. Hatsukari I., Singh P., Hitosugi N. et al. DEC-205-Mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. J. Am. Soc. Nephrol. 2007; 18: 780-787.
  34. Khan F., Proulx F., Lingwood C.A. Detergentresistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic pathology. Kidney Int 2009; 75: 1209-1216.
  35. Kapasi A.A., Fan S., Singhal P.C. p300 modulates HIV-1 gp120-induced apoptosis in human proximal tubular cells: associated with alteration of TGF-beta and Smad signaling. Nephron Exp. Nephrol. 2006; 102: e30-e38.
  36. Winston J.A., Bruggeman L.A., Ross M.D. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 2001; 344: 1979-1984.
  37. Freedman B.I., Soucie J.M., Stone S.M. et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am. J. Kidney Dis. 1999; 34: 254-258.
  38. Papeta N., Chan K.T., Prakash S. et al. Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J. Clin. Invest. 2009; 119: 1178-1188.
  39. Nunez M., Saran A.M., Freedman B.I. Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene. Adv. Chronic Kidney Dis. 2010; 17(1): 44-51.
  40. Kopp J.B., Smith M.W., Nelson G.W. et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 2008; 40: 1175-1184.
  41. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol. Dial. Transplant. 2009; 24(11): 3366-3371.
  42. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009; 75(7): 736-745.
  43. Woolley I.J., Kalayjian R., Valdez H. et al. HIV nephropathy and the Duffy antigen/receptor for Chemokines in African Americans. J. Nephrol. 2001; 14(5): 384-387.
  44. Atta M.G., Choi M.J., Longenecker J.C. et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005:118-1288.
  45. Szczech L.A., Gupta S.K., Habash R. et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004; 66(3): 1145-1152.
  46. Abbott K.C., Hypolite I., Welch P.G. et al. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J. Nephrol. 2001; 14(5): 377-383.
  47. Laradi A., Mallet A., Beaufils H. et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Néphrologiques d'Ile de France. J. Am. Soc. Nephrol. 1998; 9(12): 2327-2335.
  48. Wali R.K., Drachenberg C.I., Papadimitrou J.C. et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352: 783-784.
  49. Szczech L.A., Edwards L.J., Sanders L.L. et al. Protease inhibitors are associated with a slowed progression HIV-related renal diseases. Clin. Nephrol. 2002; 57: 336-341.
  50. Lucas G.M., Eustace J.A., Sozio S. et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546.
  51. Schwartz E.J., Szchech L.A., Ross M.J. et al. Highly active antiretroviral therapy and the epidemic of HIV+ end stage renal disease. J. Am. Soc Nephrol. 2005; 16: 2412-2420.
  52. Daugas E., Rougier J.P., Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005; 67: 393-403.
  53. Wyatt C.M., Klotman C.E. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert. Opin. Drug. Saf. 2006; 5: 275-287.
  54. Sudano I., Spieker L.E., Noll G. et al. Cardiovascular disease in HIV infection. Am. Heart J. 2006; 151: 1147-1155.
  55. Kopp J.B., Miller K.D., Mican J.A. et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 1997; 127: 119-125.
  56. Deray D.G. Ritonavir-induced acute renal failure. Clin. Drug Investig. 1998; 16(2): 175.
  57. Verhelst D., Monge M., Meynard J.L. et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 2002; 40: 1331-1333.
  58. Karras A., Lafaurie M., Furco A. et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. 2003; 36: 1070-1073.
  59. Peyriere H., Reynes J., Rouanet J. et al. Renal dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune Defic. Syndr. 2004; 35: 269-273.
  60. Gerard L., Chazallon C., Taburet A.M. et al. Renal function in antiretroviral experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir. Ther. 2007; 12(1): 31-39.
  61. Yahaya I., Uthman A.O., Uthman M.M.B. Interventions for HIV-associated nephropathy. Cochrane Database Syst. Rew. 2009; 4: CD007183.
  62. Post F.A., Moyle G.J., Stellbrink H.J. et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J. Acquir. Immune Defic. Syndr. 2010 Apr 24. [Epub ahead of print]
  63. Kimmel P.L., Mishkin G.J., Umana W.O. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am. J. Kidney Dis. 1996; 28(2): 202-208.
  64. Wei A., Burns G.C., Williams B.A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003; 64: 1462-1471.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies